Results 151 to 160 of about 5,151 (200)
Posterior Reversible Encephalopathy Syndrome Potentially Associated With Erythropoietin Analogs: A Case Report. [PDF]
CureusShaat A, Jha AK.
europepmc +1 more source
Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]
Ther Innov Regul SciMatsumoto M +11 more
europepmc +1 more source
Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes. [PDF]
BMC NephrolNasiri H +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Journal of Oncology Nursing, 2003
Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in ...
Renita Vance, Kathy Wilkinson
+8 more sources
Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in ...
Renita Vance, Kathy Wilkinson
+8 more sources
Drugs, 2001
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Hospital Pharmacy, 2002
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Darbepoetin Alfa in Systolic Heart Failure
New England Journal of Medicine, 20131. Health homes for enrollees with chronic conditions. Document 10-024. Baltimore: Center for Medicare and Medicaid Services, November 16, 2010 (http://downloads.cms.gov/cmsgov/ archived-downloads/SMDL/downloads/SMD10024.pdf). 2. Primary and behavioral health integration grants.
Dimitrios, Farmakis +2 more
openaire +5 more sources